ACADIA Pharmaceuticals Inc. Stock Price Could Go Up After Today’s Bullish Options Activity

 ACADIA Pharmaceuticals Inc. Stock Price Could Go Up After Today's Bullish Options Activity

In today’s session ACADIA Pharmaceuticals Inc. (ACAD) registered an unusually high (4,350) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ACAD increase. With 4,350 contracts traded and 42394 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ACAD170120C00035000 closed last at: $3.4 or 8.1% down. About 851,103 shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 34.25% since March 3, 2016 and is uptrending. It has outperformed by 25.91% the S&P500.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on November, 3. They expect $-0.60 earnings per share, down 53.85% or $0.21 from last year’s $-0.39 per share. After $-0.63 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Out of 4 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $55 is the highest target while $34 is the lowest. The $47.90 average target is 72.24% above today’s ($27.81) stock price. ACADIA Pharmaceuticals has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Neutral” rating by Piper Jaffray on Friday, August 7. As per Thursday, August 27, the company rating was upgraded by Piper Jaffray. Piper Jaffray downgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Friday, August 7 to “Overweight” rating. The firm has “Overweight” rating given on Friday, January 22 by Piper Jaffray. As per Friday, September 4, the company rating was maintained by JP Morgan. Leerink Swann downgraded the shares of ACAD in a report on Tuesday, May 3 to “Market Perform” rating. Cowen & Co maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Sunday, August 9 with “Outperform” rating. Needham maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Friday, August 7 with “Buy” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Mkt Perform” rating given on Tuesday, October 4 by Leerink Swann. The firm earned “Hold” rating on Monday, August 10 by Vetr.

According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio dropped, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Baker Bros Advsrs Ltd Partnership last reported 24.52M shares in the company. The New York-based Family Management has invested 0.18% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Frontier Capital Mngmt Communication Ltd Llc reported 271,231 shares or 0.07% of all its holdings. Tekla Capital Mngmt has invested 0.48% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Fmr Ltd Co has invested 0.08% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). United Cap Finance Advisers Llc accumulated 0% or 12,767 shares. Panagora Asset Mngmt Incorporated last reported 20,787 shares in the company. Blackrock Group Inc Ltd holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 126,227 shares. First Republic Investment Management Inc has 0% invested in the company for 7,531 shares. Weatherbie Cap Ltd owns 401,642 shares or 1.85% of their US portfolio. The Massachusetts-based Massachusetts Svcs Ma has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Tci Wealth Advisors Inc, a Arizona-based fund reported 1,400 shares. Diam Co Ltd holds 158,034 shares or 0.08% of its portfolio. Allianz Asset Mngmt Ag has 131,946 shares for 0% of their US portfolio. Senator L P owns 800,000 shares or 0.42% of their US portfolio.

Insider Transactions: Since April 18, 2016, the stock had 2 insider buys, and 2 insider sales for $41.34 million net activity. Shares for $1.13M were sold by Iversen Leslie L on Monday, April 18. HARRIGAN EDMUND also bought $32,970 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Tuesday, August 16. The insider BAKER BROS. ADVISORS LP bought $43.00M. $560,033 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was sold by Baity Glenn on Monday, July 11.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $3.30 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID , is under development for the treatment of Parkinson’s disease psychosis (PDP).

ACAD Company Profile

ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

More recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: Nasdaq.com which released: “Acadia Pharmaceuticals Enters Oversold Territory (ACAD)” on October 05, 2016. Also Schaeffersresearch.com published the news titled: “Options Traders Bet On ACADIA Pharmaceuticals Inc. (ACAD) Breaking Lower” on September 30, 2016. Fool.com‘s news article titled: “Why ACADIA Pharmaceuticals Tumbled 13.3% in August” with publication date: September 11, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment